SCHEMBL21738822

SCHEMBL21738822

COC(=O)/C(C)=C(/C)c1ccc(C)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 4/20 0.57
ALDH1A1 P00352 7/20 0.53
MAPT P10636 3/20 0.53
KDM4E B2RXH2 1/20 0.53
GAA P10253 1/20 0.48
LMNA P02545 2/20 0.48
CES2 O00748 2/20 0.48
CES1 P23141 2/20 0.48
HDAC1 Q13547 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.46
NPC1 O15118 4/20 0.44
RAB9A P51151 4/20 0.44
PKM P14618 2/20 0.43
HTT P42858 2/20 0.43
ATM Q13315 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
HPGD P15428 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10617986 0.82 CA1 (0.59) MAPTCES2CES1SMN1; SMN2NPC1
SCHEMBL6049096 0.82 CA1 (0.59) MAPTCES2CES1SMN1; SMN2NPC1
SCHEMBL14868118 0.81 TSHR (0.56) TDP1ALDH1A1MAPTKDM4ELMNA
SCHEMBL15081529 0.81 TSHR (0.56) TDP1ALDH1A1MAPTKDM4ELMNA
SCHEMBL14868116 0.81 TSHR (0.56) TDP1ALDH1A1MAPTKDM4ELMNA
SCHEMBL3757531 0.78 CES2 (0.65) TDP1ALDH1A1MAPTKDM4EGAA
SCHEMBL23581791 0.78 HPGD (0.48) TDP1ALDH1A1MAPTKDM4EGAA
SCHEMBL6743518 0.76 ALDH1A1 (0.58) TDP1ALDH1A1MAPTGAALMNA
SCHEMBL9300725 0.75 TDP1 (0.57) TDP1ALDH1A1MAPTKDM4EGAA
SCHEMBL7991716 0.75 CES2 (0.60) TDP1ALDH1A1MAPTKDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200055873-A1 NITROGEN-CONTAINING TRICYCLIC DERIVATIVES HAVING HIV REPLICATION INHIBITORY ACTIVITY SHIONOGI & CO., LTD. (JP) 2020-02-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200055873-A1 NITROGEN-CONTAINING TRICYCLIC DERIVATIVES HAVING HIV REPLICATION INHIBITORY ACTIVITY NR4A3, CCR3, NCOA3 TDP1 2564/4885ALDH1A1 4179/4885MAPT 4604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.